StrataPATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Enfortumab vedotin (Primary) ; Lorlatinib (Primary) ; Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary) ; Talazoparib (Primary) ; Trastuzumab-deruxtecan (Primary)
Indications Solid tumours
Focus Biomarker; Therapeutic Use
Acronyms StrataPATH
Sponsors Strata Oncology

08 Jan 2025 Status changed from active, no longer recruiting to discontinued due to business decision and enrollment difficulties
20 May 2024 Status changed from recruiting to active, no longer recruiting.
07 May 2024 According to a Gilead Sciences media release, data from this trial to be presented in abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com